• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

Introduction to 4-(4-Piperidinyl)morpholine dihydrochloride (CAS No. 550370-31-5) in Modern Chemical and Pharmaceutical Research

4-(4-Piperidinyl)morpholine dihydrochloride, identified by the chemical abstracts service number 550370-31-5, is a compound of significant interest in the realm of medicinal chemistry and pharmacology. This compound belongs to the morpholine class of heterocyclic amines, characterized by its unique structural framework that combines a morpholine ring with a piperidine moiety. The presence of two hydrochloride salts enhances its solubility and stability, making it a valuable intermediate in the synthesis of various pharmaceutical agents.

The structural configuration of 4-(4-Piperidinyl)morpholine dihydrochloride imparts distinct pharmacological properties that have garnered attention from researchers exploring novel therapeutic avenues. The morpholine ring, known for its ability to enhance bioavailability and metabolic stability, interacts synergistically with the piperidine group, which is often associated with central nervous system (CNS) activity. This combination suggests potential applications in the development of drugs targeting neurological disorders, including but not limited to depression, anxiety, and neurodegenerative diseases.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding affinities and interactions of 4-(4-Piperidinyl)morpholine dihydrochloride with various biological targets. Studies indicate that this compound exhibits promising binding properties with serotonin receptors, particularly 5-HT1A and 5-HT2A subtypes. Such interactions are crucial for developing drugs that modulate serotonin levels, which play a pivotal role in mood regulation and cognitive functions.

In addition to its potential in CNS disorders, 4-(4-Piperidinyl)morpholine dihydrochloride has shown promise in the treatment of inflammatory conditions. Research has demonstrated that the compound can inhibit the activity of enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are key mediators of inflammation. By modulating these pathways, 4-(4-Piperidinyl)morpholine dihydrochloride may offer a novel approach to managing chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The synthesis of 4-(4-Piperidinyl)morpholine dihydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including transition metal-catalyzed cross-coupling reactions and asymmetric hydrogenation, have been employed to optimize the synthetic route. These techniques not only improve efficiency but also minimize unwanted byproducts, ensuring the final product meets stringent pharmaceutical standards.

Quality control and analytical characterization are critical aspects of working with 4-(4-Piperidinyl)morpholine dihydrochloride. Techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are routinely employed to confirm purity and structural integrity. These analytical methods provide detailed insights into the compound's chemical properties, ensuring consistency across batches and facilitating its use in downstream applications.

The pharmacokinetic profile of 4-(4-Piperidinyl)morpholine dihydrochloride is another area of active investigation. Studies have revealed that this compound exhibits moderate oral bioavailability and a favorable half-life, suggesting potential for once-daily dosing regimens. Additionally, its metabolic pathways have been explored to identify key enzymes involved in its degradation, which is essential for understanding potential drug-drug interactions.

Preclinical studies have provided preliminary evidence supporting the therapeutic potential of 4-(4-Piperidinyl)morpholine dihydrochloride in various disease models. In animal models of depression, for instance, administration of this compound has been associated with reductions in behavioral despair and improved cognitive function. Similarly, studies in inflammation models have shown significant reductions in pro-inflammatory cytokine levels following treatment with 4-(4-Piperidinyl)morpholine dihydrochloride.

The development of novel drug candidates is an iterative process that involves continuous refinement based on preclinical data. Researchers are exploring derivatives of 4-(4-Piperidinyl)morpholine dihydrochloride to enhance its pharmacological properties further. By modifying specific functional groups or introducing additional substituents, scientists aim to optimize efficacy while minimizing side effects.

The role of computational tools in drug discovery cannot be overstated. Molecular docking simulations have been instrumental in identifying potential binding sites on target proteins for 4-(4-Piperidinyl)morpholine dihydrochloride. These simulations help predict how the compound interacts with biological targets at a molecular level, providing valuable insights for rational drug design.

Ethical considerations are paramount throughout the research and development process involving compounds like 4-(4-Piperidinyl)morpholine dihydrochloride. Ensuring compliance with regulatory guidelines and conducting rigorous safety assessments are essential steps before transitioning from preclinical to clinical trials. This approach safeguards both human health and scientific integrity.

The future prospects for 4-(4-Piperidinyl)morpholine dihydrochloride appear promising as ongoing research continues to uncover new therapeutic applications. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory agencies will be crucial in advancing this compound from laboratory research to clinical use. As our understanding of biological mechanisms evolves, so too will our ability to harness the potential of molecules like 4-(4-Piperidinyl)morpholine dihydrochloride for improving human health.

• 216985-68-1(4-(2-(Piperidin-2-yl)ethyl)morpholine)
• 898808-60-1(4-MORPHOLINEPROPANAMINE, N-METHYL-N-4-PIPERIDINYL-)
• 858453-96-0(4-(morpholin-4-yl)azepane)
• 88472-69-9(Morpholine, 4,4'-(1,3-dimethyl-1,3-propanediyl)bis-)
• 36882-02-7(Morpholine, 4-(1-methyl-4-piperidinyl)-)
• 334942-10-8(4-(4-piperidyl)morpholine;dihydrochloride)
• 53617-35-9(4-(piperidin-4-yl)morpholine)
• 930604-28-7(4-(4-Methylpiperidin-4-yl)Morpholine dihydrochloride)
• 1032757-76-8(4-Piperidinamine, n-(2-methoxyethyl)-n-methyl-, hydrochloride (1:1))
• 1185304-40-8(3-(4-Morpholinyl)-8-azabicyclo3.2.1octane Dihydrochloride)